{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:29:36Z","timestamp":1794670176654,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T00:00:00Z","timestamp":1520553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12967-018-1427-5","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T13:10:01Z","timestamp":1520601001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Low dose Naltrexone for induction of remission in inflammatory bowel disease patients"],"prefix":"10.1186","volume":"16","author":[{"given":"Mitchell R. K. L.","family":"Lie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"van der Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenny M.","family":"Fuhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maikel P.","family":"Peppelenbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cokkie","family":"van der Ent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Janneke","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,9]]},"reference":[{"key":"1427_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/ajg.2008.88","volume":"104","author":"JP Gisbert","year":"2009","unstructured":"Gisbert JP, Pan\u00e9s J. Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review. Am J Gastroenterol. 2009;104:760\u20137. https:\/\/doi.org\/10.1038\/ajg.2008.88 .","journal-title":"Am J Gastroenterol."},{"key":"1427_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/ajg.2011.60","volume":"106","author":"V Billioud","year":"2011","unstructured":"Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review. Am J Gastroenterol. 2011;106:674\u201384.","journal-title":"Am J Gastroenterol."},{"key":"1427_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/apt.12834","volume":"40","author":"NH Khan","year":"2014","unstructured":"Khan NH, Almukhtar RM, Cole EB, Abbas AM. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease\u2014a nationwide study of 1035 patients. Aliment Pharmacol Ther. 2014;40:374\u201381. https:\/\/doi.org\/10.1111\/apt.12834 .","journal-title":"Aliment Pharmacol Ther."},{"key":"1427_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ajg.2009.579","volume":"105","author":"L Peyrin-Biroulet","year":"2010","unstructured":"Peyrin-Biroulet L, Loftus EV, Colombel J-F, Sandborn WJ. The natural history of adult Crohn\u2019s disease in population-based cohorts. Am J Gastroenterol. 2010;105:289\u201397.","journal-title":"Am J Gastroenterol."},{"key":"1427_CR5","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1136\/gut.2007.141648","volume":"58","author":"AR Mani","year":"2009","unstructured":"Mani AR, Moore KP. New insights into the role of endogenous opioids in the pathogenesis of gastrointestinal and liver disease. Gut. 2009;58:893\u20135.","journal-title":"Gut."},{"key":"1427_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/gut.2005.084418","volume":"55","author":"S Collins","year":"2006","unstructured":"Collins S, Verma-Gandhu M. The putative role of endogenous and exogenous opiates in inflammatory bowel disease. Gut. 2006;55:756\u20137.","journal-title":"Gut."},{"key":"1427_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/gut.2005.080887","volume":"55","author":"D Philippe","year":"2006","unstructured":"Philippe D, Chakass D, Thuru X, Zerbib P, Tsicopoulos A, Geboes K, et al. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut. 2006;55:815\u201323. https:\/\/doi.org\/10.1136\/gut.2005.080887 .","journal-title":"Gut."},{"key":"1427_CR8","doi-asserted-by":"crossref","unstructured":"Philippe D, Dubuquoy L, Groux H, Brun V, Chuo\u00ef-Mariot MT Van, Gaveriaux-Ruff C, et al. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest. 2003;111:1329\u201338. http:\/\/www.jci.org\/articles\/view\/16750 . Accessed 15 Dec 2016.","DOI":"10.1172\/JCI16750"},{"key":"1427_CR9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0022-3565(25)10212-7","volume":"264","author":"KL Preston","year":"1993","unstructured":"Preston KL, Bigelow GE. Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther. 1993;264:813\u201323.","journal-title":"J Pharmacol Exp Ther."},{"key":"1427_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.mehy.2008.06.048","volume":"72","author":"N Brown","year":"2009","unstructured":"Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses. 2009;72:333\u20137.","journal-title":"Med Hypotheses."},{"key":"1427_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.psym.2011.11.006","volume":"53","author":"S Ramanathan","year":"2012","unstructured":"Ramanathan S, Panksepp J, Johnson B. Is fibromyalgia an endocrine\/endorphin deficit disorder? Is low dose naltrexone a new treatment option? Psychosomatics. 2012;53:591\u20134.","journal-title":"Psychosomatics."},{"key":"1427_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","volume":"10","author":"J Younger","year":"2009","unstructured":"Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10:663\u201372.","journal-title":"Pain Med."},{"key":"1427_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jhep.2012.03.031","volume":"57","author":"T Folseraas","year":"2012","unstructured":"Folseraas T, Melum E, Rausch P, Juran BD, Ellinghaus E, Shiryaev A, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol. 2012;57:366\u201375.","journal-title":"J Hepatol."},{"key":"1427_CR14","doi-asserted-by":"crossref","unstructured":"Turel AP, Oh KH, Zagon IS, McLaughlin PJ. Low dose naltrexone for treatment of multiple sclerosis: a retrospective chart review of safety and tolerability. J Clin Psychopharmacol. 2015;35:609\u201311. http:\/\/content.wkhealth.com\/linkback\/openurl?sid=WKPTLP:landingpage&an=00004714-201510000-00020 . Accessed 20 Dec 2016.","DOI":"10.1097\/JCP.0000000000000373"},{"key":"1427_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/15476910802131469","volume":"5","author":"GL Matters","year":"2008","unstructured":"Matters GL, Harms JF, McGovern C, Fitzpatrick L, Parikh A, Nilo N, et al. The opioid antagonist naltrexone improves murine inflammatory bowel disease. J Immunotoxicol. 2008;5:179\u201387.","journal-title":"J Immunotoxicol."},{"key":"1427_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.npep.2016.06.003","volume":"59","author":"DI Tawfik","year":"2016","unstructured":"Tawfik DI, Osman AS, Tolba HM, Khattab A, Abdel-Salam LO, Kamel MM. Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn\u2019s disease in rats. Neuropeptides. 2016;59:39\u201345.","journal-title":"Neuropeptides."},{"key":"1427_CR17","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/gutjnl-2012-303527","volume":"63","author":"JJ Deuring","year":"2014","unstructured":"Deuring JJ, Fuhler GM, Konstantinov SR, Peppelenbosch MP, Kuipers EJ, de Haar C, et al. Genomic ATG16L1 risk allele-restricted Paneth cell ER stress in quiescent Crohn\u2019s disease. Gut. 2014;63:1081\u201391.","journal-title":"Gut."},{"key":"1427_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nri.2016.62","volume":"16","author":"J Grootjans","year":"2016","unstructured":"Grootjans J, Kaser A, Kaufman RJ, Blumberg RS. The unfolded protein response in immunity and inflammation. Nat Rev Immunol. 2016;16:469\u201384.","journal-title":"Nat Rev Immunol."},{"key":"1427_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.cell.2008.07.021","volume":"134","author":"A Kaser","year":"2008","unstructured":"Kaser A, Lee A-H, Franke A, Glickman JN, Zeissig S, Tilg H, et al. XBP1 Links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell. 2008;134:743\u201356.","journal-title":"Cell."},{"key":"1427_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/1440-1681.12695","volume":"44","author":"A Moslehi","year":"2016","unstructured":"Moslehi A, Nabavizadeh F, Zekri A, Amiri F. Naltrexone changes the expression of lipid metabolism-related proteins in the endoplasmic reticulum (ER) stress induced hepatic steatosis in mice. Clin Exp Pharmacol Physiol. 2016;44:207\u201312.","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"1427_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1556\/APhysiol.101.2014.3.9","volume":"101","author":"A Moslehi","year":"2014","unstructured":"Moslehi A, Nabavizadeh F, Dehpou AR, Tavanga SM, Hassanzadeh G, Zekri A, et al. Naltrexone attenuates endoplasmic reticulum stress induced hepatic injury in mice. Acta Physiol Hung. 2014;101:341\u201352.","journal-title":"Acta Physiol Hung."},{"key":"1427_CR22","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","volume":"102","author":"JP Smith","year":"2007","unstructured":"Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn\u2019s disease. Am J Gastroenterol. 2007;102:820\u20138. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01045.x .","journal-title":"Am J Gastroenterol."},{"key":"1427_CR23","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","volume":"56","author":"JP Smith","year":"2011","unstructured":"Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn\u2019s disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56:2088\u201397.","journal-title":"Dig Dis Sci."},{"key":"1427_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/MCG.0b013e3182702f2b","volume":"47","author":"JP Smith","year":"2013","unstructured":"Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn\u2019s disease: a pilot study. J Clin Gastroenterol. 2013;47:339\u201345.","journal-title":"J Clin Gastroenterol."},{"key":"1427_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nm.3201","volume":"19","author":"JF Dekkers","year":"2013","unstructured":"Dekkers JF, Wiegerinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med. 2013;19:939\u201345.","journal-title":"Nat Med."},{"key":"1427_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.antiviral.2016.07.017","volume":"133","author":"Y Yin","year":"2016","unstructured":"Yin Y, Wang Y, Dang W, Xu L, Su J, Zhou X, et al. Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. Antiviral Res. 2016;133:41\u20139.","journal-title":"Antiviral Res."},{"key":"1427_CR27","doi-asserted-by":"publisher","first-page":"e45362","DOI":"10.1371\/journal.pone.0045362","volume":"7","author":"KCS Queiroz","year":"2012","unstructured":"Queiroz KCS, Milani R, Ruela-de-Sousa RR, Fuhler GM, Justo GZ, Zambuzzi WF, et al. Violacein induces death of resistant leukaemia cells via kinome reprogramming, endoplasmic reticulum stress and Golgi apparatus collapse. PLoS ONE. 2012;7:e45362.","journal-title":"PLoS ONE."},{"key":"1427_CR28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.eururo.2015.06.040","volume":"69","author":"RR Ruela-de-Sousa","year":"2016","unstructured":"Ruela-de-Sousa RR, Hoekstra E, Hoogland AM, Souza Queiroz KC, Peppelenbosch MP, Stubbs AP, et al. Low-molecular-weight protein tyrosine phosphatase predicts prostate cancer outcome by increasing the metastatic potential. Eur Urol. 2016;69:710\u20139.","journal-title":"Eur Urol."},{"key":"1427_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1600-0609.2009.01263.x","volume":"83","author":"GM Fuhler","year":"2009","unstructured":"Fuhler GM, Tyl MR, Olthof SGM, Lyndsay Drayer A, Blom N, Vellenga E. Distinct roles of the mTOR components Rictor and Raptor in MO7e megakaryocytic cells. Eur J Haematol. 2009;83:235\u201345.","journal-title":"Eur J Haematol."},{"key":"1427_CR30","doi-asserted-by":"crossref","first-page":"73525","DOI":"10.18632\/oncotarget.12321","volume":"7","author":"E Hoekstra","year":"2016","unstructured":"Hoekstra E, Das AM, Willemsen M, Swets M, Kuppen PJK, van der Woude CJ, et al. Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation. Oncotarget. 2016;7:73525.","journal-title":"Oncotarget."},{"key":"1427_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1053\/j.gastro.2013.09.020","volume":"146","author":"J Bou\u00e9","year":"2014","unstructured":"Bou\u00e9 J, Basso L, Cenac N, Blanpied C, Rolli-Derkinderen M, Neunlist M, et al. Endogenous regulation of visceral pain via production of opioids by colitogenic CD4+ T cells in mice. Gastroenterology. 2014;146:166\u201375.","journal-title":"Gastroenterology."},{"key":"1427_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/nmo.12008","volume":"25","author":"E Valdez-Morales","year":"2013","unstructured":"Valdez-Morales E, Guerrero-Alba R, Ochoa-Cortes F, Benson J, Spreadbury I, Hurlbut D, et al. Release of endogenous opioids during a chronic IBD model suppresses the excitability of colonic DRG neurons. Neurogastroenterol Motil. 2013;25:39.","journal-title":"Neurogastroenterol Motil."},{"key":"1427_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejphar.2012.03.014","volume":"683","author":"C Alt","year":"2012","unstructured":"Alt C, Lam JS, Harrison MT, Kershaw KM, Samuelsson S, Toll L, et al. Nociceptin\/orphanin FQ inhibition with SB612111 ameliorates dextran sodium sulfate-induced colitis. Eur J Pharmacol. 2012;683:285\u201393.","journal-title":"Eur J Pharmacol."},{"key":"1427_CR34","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/bph.13394","volume":"173","author":"X Wang","year":"2016","unstructured":"Wang X, Zhang Y, Peng Y, Hutchinson MR, Rice KC, Yin H, et al. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. Br J Pharmacol. 2016;173:856\u201369. https:\/\/doi.org\/10.1111\/bph.13394 .","journal-title":"Br J Pharmacol."},{"key":"1427_CR35","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tips.2014.07.002","volume":"35","author":"LR Watkins","year":"2014","unstructured":"Watkins LR, Wang X, Mustafa S, Hutchinson MR. In vivo veritas: (+)-Naltrexone\u2019s actions define translational importance: a letter in response to Skolnick et al. \u201cTranslational potential of naloxone and naltrexone as TLR4 antagonists\u201d. Trends Pharmacol Sci. 2014;35:432\u20133.","journal-title":"Trends Pharmacol Sci."},{"key":"1427_CR36","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1177\/1535370213502632","volume":"238","author":"JA Immonen","year":"2013","unstructured":"Immonen JA, Zagon IS, Lewis GS, McLaughlin PJ. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats. Exp Biol Med. 2013;238:1127\u201335.","journal-title":"Exp Biol Med."},{"key":"1427_CR37","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1177\/1535370214543061","volume":"239","author":"JA Immonen","year":"2014","unstructured":"Immonen JA, Zagon IS, McLaughlin PJ. Featured article: selective blockade of the OGF\u2013OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing. Exp Biol Med. 2014;239:1300\u20139.","journal-title":"Exp Biol Med."},{"key":"1427_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1042\/BJ20111281","volume":"441","author":"JJ Deuring","year":"2012","unstructured":"Deuring JJ, de Haar C, Koelewijn CL, Kuipers EJ, Peppelenbosch MP, van der Woude CJ. Absence of ABCG2-mediated mucosal detoxification in patients with active inflammatory bowel disease is due to impeded protein folding. Biochem J. 2012;441:87\u201393.","journal-title":"Biochem J."},{"key":"1427_CR39","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1042\/BST0391107","volume":"39","author":"JJ Deuring","year":"2011","unstructured":"Deuring JJ, Peppelenbosch MP, Kuipers EJ, van der Woude CJ. Impeded protein folding and function in active inflammatory bowel disease. Biochem Soc Trans. 2011;39:1107\u201311.","journal-title":"Biochem Soc Trans."},{"key":"1427_CR40","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160791","author":"M Tschurtschenthaler","year":"2017","unstructured":"Tschurtschenthaler M, Adolph TE, Ashcroft JW, Niederreiter L, Bharti R, Saveljeva S, et al. Defective ATG16L1-mediated removal of IRE1\u03b1 drives Crohn\u2019s disease-like ileitis. J Exp Med. 2017. https:\/\/doi.org\/10.1084\/jem.20160791 .","journal-title":"J Exp Med."},{"key":"1427_CR41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","volume":"65","author":"RF Anton","year":"2008","unstructured":"Anton RF, Oroszi G, O\u2019Malley S, Couper D, Swift R, Pettinati H, et al. An evaluation of \u03bc-opioid receptor (OPRM1) as a predictor of Naltrexone response in the treatment of alcohol dependence. Arch Gen Psychiatry. 2008;65:135.","journal-title":"Arch Gen Psychiatry"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1427-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-018-1427-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1427-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T16:59:23Z","timestamp":1751475563000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-018-1427-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,9]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1186\/s12967-018-1427-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,9]]},"assertion":[{"value":"27 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"55"}}